Final Overall Survival Analysis of CONFIRM Trial of 500 mg versus 250 mg of Fulvestrant


Final Overall Survival Analysis of CONFIRM Trial of 500 mg versus 250 mg of Fulvestrant
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Lisa A Carey, MD (1/17/13)
Di Leo A et al. Final analysis of overall survival for the Phase III CONFIRM trial: Fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium 2012;Abstract S1-4.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.